AR094141A1 - Composiciones y metodos para proteinas de accion prolongada - Google Patents
Composiciones y metodos para proteinas de accion prolongadaInfo
- Publication number
- AR094141A1 AR094141A1 ARP130104864A ARP130104864A AR094141A1 AR 094141 A1 AR094141 A1 AR 094141A1 AR P130104864 A ARP130104864 A AR P130104864A AR P130104864 A ARP130104864 A AR P130104864A AR 094141 A1 AR094141 A1 AR 094141A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- peptide
- subject
- composition
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4718—Cytokine-induced proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Abstract
Marcador peptídico que se fija a ácido hialurónico (HA) y que comprende una secuencia seleccionada del grupo que consiste de a) SEQ ID Nº 33, SEC ID Nº 34, SEC ID Nº 35 y SEQ ID Nº 36; o b) 95 aminoácidos consecutivos de la secuencia de SEQ ID Nº 33, SEC ID Nº 34, SEC ID Nº 35 o SEQ ID Nº 36, una molécula marcada con péptido que comprende el marcador peptídico, una composición que comprende una molécula marcada con péptido, y un proceso para la producción de un marcador peptídico. Reivindicación 14: Una composición que comprende una molécula marcada con péptido como se reivindica en cualquiera de las reivindicaciones 2 - 13 y un excipiente, diluyente o vehículo farmacéuticamente aceptable. Reivindicación 17: Un ácido nucleico que codifica un marcador peptídico de la reivindicación 1. Reivindicación 30: Un método de tratamiento de una afección o trastorno del ojo en un sujeto, el cual comprende administrar al sujeto una composición tal como se reivindica en una cualquiera de las reivindicaciones 14 - 16. Reivindicación 34: La composición tal como se reivindica en cualquiera de las reivindicaciones 14 a 16 para utilizar en el tratamiento en un sujeto de una afección o trastorno asociado con edema macular. Reivindicación 39: Un método de tratamiento de un trastorno mediada por VEGF en un sujeto, el cual comprende la etapa de administración al sujeto de una composición que comprende un marcador peptídico tal como se reivindica en la reivindicación 1 unido a un anticuerpo anti-VEGF o fragmento de unión al antígeno del mismo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261738488P | 2012-12-18 | 2012-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR094141A1 true AR094141A1 (es) | 2015-07-15 |
Family
ID=49917282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104864A AR094141A1 (es) | 2012-12-18 | 2013-12-19 | Composiciones y metodos para proteinas de accion prolongada |
Country Status (17)
Country | Link |
---|---|
US (2) | US20140186350A1 (es) |
EP (1) | EP2935589A1 (es) |
JP (1) | JP2016502850A (es) |
KR (1) | KR20150095684A (es) |
CN (1) | CN104995303A (es) |
AR (1) | AR094141A1 (es) |
AU (1) | AU2013362909A1 (es) |
BR (1) | BR112015013861A2 (es) |
CA (1) | CA2891686A1 (es) |
CL (1) | CL2015001709A1 (es) |
EA (1) | EA201591176A1 (es) |
MX (1) | MX2015007931A (es) |
PH (1) | PH12015501352A1 (es) |
SG (1) | SG11201503566QA (es) |
TW (1) | TW201427989A (es) |
UY (1) | UY35195A (es) |
WO (1) | WO2014099997A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2280720T3 (en) | 2008-03-27 | 2019-06-11 | Purdue Research Foundation | COLLAGEN BINDING SYNTHETIC PEPTIDOGLYCANES, MANUFACTURING AND PROCEDURE FOR USE |
EP2547323B1 (en) | 2010-03-17 | 2016-01-27 | Novaliq GmbH | Pharmaceutical composition for treatment of increased intraocular pressure |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
KR102006036B1 (ko) | 2011-05-24 | 2019-07-31 | 시믹 아이피, 엘엘씨 | 히알루론산-결합 합성 펩티도글리칸 및 이의 제조 및 이용 방법 |
EP4342537A2 (en) | 2012-09-12 | 2024-03-27 | Novaliq GmbH | Semifluorinated alkane compositions |
JP6603650B2 (ja) | 2013-03-15 | 2019-11-06 | パーデュー・リサーチ・ファウンデーション | 細胞外マトリックス結合性合成ペプチドグリカン |
WO2015095972A1 (en) | 2013-12-23 | 2015-07-02 | The Centre For Drug Research And Development | Antibodies comprising c-terminal light chain polypeptide extensions and conjugates and methods of use thereof |
US10772931B2 (en) | 2014-04-25 | 2020-09-15 | Purdue Research Foundation | Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction |
WO2015198240A2 (en) * | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
WO2015198243A2 (en) * | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for long acting proteins |
CA2953682A1 (en) * | 2014-06-25 | 2015-12-30 | Novartis Ag | Compositions and methods for visualization of the vitreous |
EP3161001A2 (en) * | 2014-06-25 | 2017-05-03 | Novartis AG | Antibodies specific for il-17a fused to hyaluronan binding peptide tags |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
US20180230540A1 (en) | 2015-08-12 | 2018-08-16 | Novartis Ag | Methods of treating ophthalmic disorders |
WO2017053807A2 (en) | 2015-09-23 | 2017-03-30 | Genentech, Inc. | Optimized variants of anti-vegf antibodies |
JP6602964B2 (ja) | 2015-09-30 | 2019-11-06 | ノバリック ゲーエムベーハー | 半フッ素化化合物およびその組成物 |
US20180293360A1 (en) | 2015-10-07 | 2018-10-11 | Genentech, Inc. | Systems and methods for predicting vitreal half-life of therapeutic agent-polymer conjugates |
RU2744860C2 (ru) | 2015-12-30 | 2021-03-16 | Кодиак Сайенсиз Инк. | Антитела и их конъюгаты |
CN109072241A (zh) * | 2016-02-08 | 2018-12-21 | 维特里萨医疗公司 | 具有改善的玻璃体内半衰期的组合物及其用途 |
CN109311964B (zh) | 2016-06-06 | 2022-11-04 | 豪夫迈·罗氏有限公司 | 用于眼科的具有增加的眼保留的融合蛋白 |
JP6869336B2 (ja) | 2016-09-23 | 2021-05-12 | ノバリック ゲーエムベーハー | シクロスポリンを含む眼科用組成物 |
WO2018055014A1 (en) * | 2016-09-23 | 2018-03-29 | Ventana Medical Systems, Inc. | Methods and systems for scoring extracellular matrix biomarkers in tumor samples |
CN106636102A (zh) * | 2016-10-17 | 2017-05-10 | 柳州立洁科技有限公司 | 一种高亲和力***核酸适体epo4及其制备方法 |
AU2017384650B2 (en) * | 2016-12-23 | 2021-02-18 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
SG10202107829YA (en) | 2017-03-22 | 2021-08-30 | Genentech Inc | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
EP3619235A1 (en) | 2017-04-11 | 2020-03-11 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
EP3621601A1 (en) | 2017-05-12 | 2020-03-18 | Novaliq GmbH | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
EP3648774A4 (en) | 2017-07-07 | 2021-04-21 | Symic IP, LLC | SYNTHETIC ORGANIC CONJUGATES |
CN111344002A (zh) | 2017-08-31 | 2020-06-26 | 新加坡保健服务集团 | 用于治疗视网膜血管生成性疾病的Angio-3 |
KR20200059272A (ko) | 2017-09-27 | 2020-05-28 | 노바리크 게엠베하 | 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물 |
WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
CN107723310B (zh) * | 2017-10-19 | 2024-01-09 | 北京睿诚海汇健康科技有限公司 | 植物作为宿主在表达卡那抗体中的应用 |
US20190330366A1 (en) | 2018-04-11 | 2019-10-31 | Inhibrx, Inc. | Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses |
GB201806918D0 (en) * | 2018-04-27 | 2018-06-13 | Enleofen Bio Pte Ltd | Combination treatment for eye fibrosis |
US20200048350A1 (en) | 2018-07-24 | 2020-02-13 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
TW202021986A (zh) | 2018-10-11 | 2020-06-16 | 美商英伊布里克斯公司 | 5t4單域抗體及其治療性組合物 |
US11208485B2 (en) | 2018-10-11 | 2021-12-28 | Inhibrx, Inc. | PD-1 single domain antibodies and therapeutic compositions thereof |
EP3864045A2 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
CN113166261A (zh) | 2018-10-11 | 2021-07-23 | 印希比股份有限公司 | B7h3单域抗体及其治疗性组合物 |
AU2019358249B2 (en) | 2018-10-12 | 2024-02-22 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
CN115417914A (zh) * | 2019-10-11 | 2022-12-02 | 润辉生物技术(威海)有限公司 | 一种乙酰透明质酸寡肽及其制备与应用方法 |
IL294879A (en) | 2020-01-29 | 2022-09-01 | Inhibrx Inc | Monodomain antibodies of cd28 and their multivalent and multispecific constructs |
IL299048A (en) * | 2020-06-14 | 2023-02-01 | Vertex Pharma | Variants of complement factor - 1 fusion structures and preparations containing them and their uses |
TW202216761A (zh) * | 2020-07-16 | 2022-05-01 | 瑞士商諾華公司 | 抗β細胞素抗體、其片段及多特異性結合分子 |
IL302089A (en) | 2020-10-15 | 2023-06-01 | Hoffmann La Roche | Non-covalent protein-hyaluronan conjugates for long-term ocular delivery |
WO2022098787A1 (en) | 2020-11-04 | 2022-05-12 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
WO2022223140A1 (en) * | 2021-04-23 | 2022-10-27 | Navigo Proteins Gmbh | Fusion proteins with specifity for type ii collagen and vegf-a for the treatment of eye diseases |
WO2023034903A1 (en) * | 2021-09-01 | 2023-03-09 | 3Helix, Inc. | Systems and methods for detecting fibrosis |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
ATE120761T1 (de) | 1987-05-21 | 1995-04-15 | Creative Biomolecules Inc | Multifunktionelle proteine mit vorbestimmter zielsetzung. |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DE69120146T2 (de) | 1990-01-12 | 1996-12-12 | Cell Genesys Inc | Erzeugung xenogener antikörper |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992010591A1 (en) | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
CA2196200A1 (en) | 1994-07-29 | 1996-02-15 | Michael Joseph Browne | Novel compounds |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
EP0973804B1 (en) | 1997-04-07 | 2006-12-27 | Genentech, Inc. | Anti-vegf antibodies |
CA2304254C (en) | 1997-06-11 | 2012-05-22 | Hans Christian Thogersen | Trimerising module |
US6673901B2 (en) | 1997-06-12 | 2004-01-06 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
EP2829609A1 (en) | 1999-08-24 | 2015-01-28 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
WO2002057445A1 (en) | 2000-05-26 | 2002-07-25 | National Research Council Of Canada | Single-domain brain-targeting antibody fragments derived from llama antibodies |
ATE318923T1 (de) | 2000-06-01 | 2006-03-15 | Univ North Carolina | Doppelsträngige parvovirus-vektoren |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
WO2002092780A2 (en) | 2001-05-17 | 2002-11-21 | Diversa Corporation | Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
WO2004050027A2 (en) | 2002-12-02 | 2004-06-17 | Genvec, Inc. | Materials and methods for treating ocular-related disorders |
JP5026072B2 (ja) | 2003-07-01 | 2012-09-12 | イミューノメディクス、インコーポレイテッド | 二重特異性抗体の多価キャリヤー |
AU2005207003C1 (en) | 2004-01-20 | 2013-06-13 | Humanigen, Inc. | Antibody specificity transfer using minimal essential binding determinants |
JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
US7723472B2 (en) * | 2005-02-28 | 2010-05-25 | The Regents Of The University Of California | Extracellular matrix binding chimeric proteins and methods of use thereof |
RU2515108C2 (ru) | 2005-08-19 | 2014-05-10 | Эббви Инк | Иммуноглобулин с двойными вариабельными доменами и его применения |
CR20170001A (es) | 2008-04-28 | 2017-08-10 | Genentech Inc | Anticuerpos anti factor d humanizados |
CN110372792A (zh) | 2008-06-25 | 2019-10-25 | 艾斯巴技术-诺华有限责任公司 | 抑制vegf的稳定和可溶的抗体 |
KR20140014405A (ko) * | 2009-05-28 | 2014-02-06 | 글락소 그룹 리미티드 | 안구 질병을 치료하거나 예방하는데 사용되는 tnf-알파 길항제 및 vegf 길항제의 조합물 |
KR101859124B1 (ko) * | 2010-05-03 | 2018-05-21 | 더 텍사스 에이 & 엠 유니버시티 시스템 | 눈 손상 및 질환 치료용 성체 줄기 세포/전구 세포 및 줄기 세포 단백질 |
CN102971659B (zh) | 2010-06-29 | 2016-05-25 | 图象公司 | 空间上修改光的偏振状态 |
US9006319B2 (en) | 2010-07-30 | 2015-04-14 | Sabic Global Technologies B.V. | Hydrostable polyetherimide blends, methods of manufacture, and articles formed therefrom |
UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
JP2014515759A (ja) | 2011-04-29 | 2014-07-03 | ノバルティス アーゲー | 扁平上皮がんを治療する方法関連出願 |
SG11201401797TA (en) * | 2011-10-24 | 2014-09-26 | Halozyme Inc | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof |
-
2013
- 2013-12-17 WO PCT/US2013/075795 patent/WO2014099997A1/en active Application Filing
- 2013-12-17 EA EA201591176A patent/EA201591176A1/ru unknown
- 2013-12-17 TW TW102146747A patent/TW201427989A/zh unknown
- 2013-12-17 JP JP2015549586A patent/JP2016502850A/ja active Pending
- 2013-12-17 EP EP13815922.3A patent/EP2935589A1/en not_active Withdrawn
- 2013-12-17 AU AU2013362909A patent/AU2013362909A1/en not_active Abandoned
- 2013-12-17 UY UY0001035195A patent/UY35195A/es not_active Application Discontinuation
- 2013-12-17 SG SG11201503566QA patent/SG11201503566QA/en unknown
- 2013-12-17 MX MX2015007931A patent/MX2015007931A/es unknown
- 2013-12-17 KR KR1020157015849A patent/KR20150095684A/ko not_active Application Discontinuation
- 2013-12-17 BR BR112015013861A patent/BR112015013861A2/pt not_active IP Right Cessation
- 2013-12-17 CN CN201380073151.3A patent/CN104995303A/zh active Pending
- 2013-12-17 US US14/109,426 patent/US20140186350A1/en not_active Abandoned
- 2013-12-17 CA CA2891686A patent/CA2891686A1/en not_active Abandoned
- 2013-12-19 AR ARP130104864A patent/AR094141A1/es unknown
-
2015
- 2015-06-15 PH PH12015501352A patent/PH12015501352A1/en unknown
- 2015-06-17 CL CL2015001709A patent/CL2015001709A1/es unknown
-
2016
- 2016-06-17 US US15/186,025 patent/US20160297854A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CL2015001709A1 (es) | 2015-08-28 |
EA201591176A1 (ru) | 2016-02-29 |
US20140186350A1 (en) | 2014-07-03 |
SG11201503566QA (en) | 2015-09-29 |
TW201427989A (zh) | 2014-07-16 |
JP2016502850A (ja) | 2016-02-01 |
WO2014099997A1 (en) | 2014-06-26 |
MX2015007931A (es) | 2015-10-05 |
BR112015013861A2 (pt) | 2017-07-11 |
EP2935589A1 (en) | 2015-10-28 |
CN104995303A (zh) | 2015-10-21 |
UY35195A (es) | 2014-07-31 |
KR20150095684A (ko) | 2015-08-21 |
PH12015501352A1 (en) | 2015-09-07 |
AU2013362909A1 (en) | 2015-05-21 |
CA2891686A1 (en) | 2014-06-26 |
US20160297854A1 (en) | 2016-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
PE20181316A1 (es) | Nuevos peptidos y combinacion de peptidos para el uso en la inmunoterapia contra varios tipos de cancer | |
PE20170071A1 (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas | |
AR087567A1 (es) | Anticuerpos anti-tie2 y usos de los mismos | |
PE20180505A1 (es) | Peptidos y combinacion de peptidos y andamiajes novedosos para su uso en inmunoterapia contra carcinoma de celulas renales (rcc) y otros canceres | |
AR105654A1 (es) | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) | |
AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
MX2021015182A (es) | Casetes optimizados de expresion del gen humano del factor viii de coagulacion y su uso. | |
MY176332A (en) | Multispecific antibody constructs | |
PE20181517A1 (es) | Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer | |
NZ705370A (en) | Fcγriib-specific fc region variant | |
WO2017011773A3 (en) | Codon-optimized nucleic acids encoding antibodies | |
AR085281A1 (es) | Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso | |
PE20230321A1 (es) | Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer | |
EA201591131A1 (ru) | Днк-конструкции антитела и способ их применения | |
CL2009001001A1 (es) | Anticuerpo anti-factor d del complemento; polinucleotido codificante; vector que comprende dicho polinucleotido; celula huesped que comprende dicho vector; metodo de fabricacion del anticuerpo; composicion farmaceutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares. | |
AR081361A1 (es) | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a | |
PE20201067A1 (es) | Anticuerpos anti-csf 1r | |
AR085955A1 (es) | Proteinas de union al antigeno | |
RU2015119517A (ru) | Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1 | |
MX2018016114A (es) | Una novedosa fructosa-6-fosfato-3-epimerasa termoestable y un procedimiento para producir alulosa mediante el uso de la misma. | |
PE20180481A1 (es) | Anticuerpos de union a tau |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |